Guillain Barre Syndrome

The Centers for Disease Control and Prevention (CDC) recommend tetanus vaccinations for children and adults. Tetanus is a type of bacterial infection that can cause a wide range of symptoms, and that can potentially lead to fatal respiratory failure. The tetanus vaccine is generally considered safe for most people, and is specifically recommended for women who are pregnant. However, some vaccine recipients may experience severe allergic reactions, and cases of Guillain-Barre Syndrome (GBS) and vaccine-related shoulder injuries have been reported as well.

Which Type of Tetanus Vaccination Do You Need?

The tetanus vaccine comes in four different forms, and the CDC recommends different forms for individuals in different age groups.

The U.S. Court of Federal Claims (also known as the Vaccine Court) is on pace to issue a record number of awards under the National Vaccine Injury Compensation Program (VICP) in 2019. As of June 1, the Vaccine Court has issued 404 awards to vaccine recipients, totaling nearly $145 million in compensation. If the rate of awards continues, 2019’s total will surpass the previous one-year high, which was 706 awards in 2017.

Each year, hundreds of people seek financial compensation for vaccine-related injuries and illnesses. Many more suffer injuries and illnesses that are never reported; and, as researchers continue learn more about the risks associated with different types of vaccinations, more types of injuries and illnesses are being recognized as vaccine-related.

There are two primary ways that vaccine recipients can experience complications from their immunizations: (i) adverse reactions to vaccine ingredients, and (ii) errors during vaccine administration.

1. Adverse Reactions to Vaccine Ingredients

Individuals who experience adverse reactions to vaccine ingredients can face a variety of medical consequences.

Each year, the Centers for Disease Control and Prevention (CDC) choose the specific strains to be targeted with the annual flu shot based upon an examination of thousands of influenza virus samples collected from patients worldwide. The selection process is not easy, and the challenges involved in choosing the most-effective formulation of the flu vaccine in any given year are largely to blame for the flu shot’s limited effectiveness in recent years.

Now, however, scientists may have found a more-effective way to choose vaccines for future seasons. Using new “HINT” technology, scientists believe that it may now be possible to better identify the flu strains that most likely to infect people year to year.